Citizens on Acrivon Therapeutics Inc (ACRV): 'We believe this significantly improved enrollment and should help commercially, if approved'
Tweet Send to a Friend
Citizens analyst Silvan Tuerkcan reiterated a Market Outperform rating and $13.00 price target on Acrivon Therapeutics Inc (NASDAQ: ACRV)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
